サンプル依頼リスト カート
  • English
  • Korean
表紙：壊死性腸炎治療薬の世界市場-2023年～2030年
市場調査レポート
商品コード
1352126

壊死性腸炎治療薬の世界市場-2023年～2030年

Global Necrotizing Enterocolitis Drugs Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
壊死性腸炎治療薬の世界市場-2023年～2030年
出版日: 2023年09月27日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

壊死性腸炎の市場動向は、技術的進歩や調査研究の増加に起因する研究の高まりを示します。いくつかの抗生物質が壊死性腸炎の治療のために発売されています。抗真菌剤も小児科における壊死性腸炎の予防に利用されています。

さらに、承認された抗生物質の入手可能性の上昇や市場における壊死性腸炎の症例数の増加による壊死性腸炎の治療の増加、研究開発の増加が壊死性腸炎の市場規模を押し上げています。

市場は、この分野での進歩の高まりの結果、北米地域からの医薬品需要の伸びを経験しています。Noveome Biotherapeutics, Inc.、Pfizer Inc.、Endo Pharmaceuticals Inc.、Sanofiのような重要な競合企業が市場で積極的に活動しているため、市場は今後成長すると思われます。

ダイナミクス

研究開発者の増加が壊死性腸炎市場の成長を牽引

最も一般的な新生児消化器疾患の1つが壊死性腸炎（NEC）です。NECの有病率と死亡率は、予防と治療が進歩し続けているにもかかわらず、依然として高い水準にあります。NECの予防と治療は、母乳組成物の投与、免疫療法、幹細胞療法、糞便微生物叢移植（FMT）などの新しい治療アプローチによって最近進歩しています。

オリゴ糖、ラクトフェリン、母乳から生成されるエクソソーム、その他の成分を含む母乳組成は、NECを予防・治癒する最も効率的な方法の1つであることが多くの研究で示されています。初乳に最も多く含まれるタンパク質（5～6.7g/L）と母乳に最も多く含まれるタンパク質は、いずれもラクトフェリンです。ラクトフェリンによって、IL-6やTNF-を含む炎症性サイトカインの産生を防ぐことで、腸の炎症を抑えることができます。腸のバリア機能を維持することに加え、ラクトフェリンは腸上皮細胞の増殖と死滅に影響を与えます。

数多くの前臨床試験と臨床試験によって、NECの予防と治療の両方にラクトフェリンが有効であることが証明されています。TLR4の発現を減少させ、陰窩細胞のターンオーバーを促進することによって、オリゴ糖は腸上皮細胞を害から守ります。母乳から産生されるエクソソームは腸の成長を促進し、実験的NECに対して好ましい効果を示します。腸管幹細胞は、Wnt/カテニンシグナル伝達経路を介して制御されていた酸化的損傷に対して脆弱ですが、母乳由来のエクソソームはそれらを保護します。

企業による投資と資金調達の増加が市場成長の機会を創出

ピッツバーグに本社を置くバイオ医薬品会社Noveome Biotherapeutics, Inc.は、炎症または傷害を受けた組織における細胞構造の改善と再構築のための次世代生物学的製剤の開発を臨床段階で進めていますが、4,020万米ドルのシリーズE資金調達の第一弾として総額2,070万米ドルの資金調達を完了しました。MAKキャピタルが資金調達を監督し、追加資金は現在の投資家が拠出しました。

ノベオムはこれまでに個人投資家から1億7,000万米ドルの資金を調達しており、ペンシルベニア州、アレゲニー郡、米国国防総省からも非希薄化投資を受けています。今回の資金調達は、主に特許取得済みのST266無細胞生物学的製剤を用いた当社の臨床段階プログラムの推進に使用され、珍しい小児疾患である壊死性腸炎（NEC）の症状を治療します。

ST266は、ヒト羊膜由来細胞を培養したユニークな集団です。これらの細胞は、特許取得済みの培養技術により、セクレトームと呼ばれるサイトカインや成長因子の特別な集合体を産生し、細胞の生存を助け、炎症を抑えます。

壊死性腸炎の手術費用の高さが市場の成長を妨げる

NECの管理は非常に高額です。調査によると、米国におけるNECの手術症例は通常40～50万米ドルかかります。病院支出を考慮した前向き研究によると、NECの手術の価格は30万米ドルから66万米ドルでした。NECの治療に選択される外科的処置は、病院経費に大きな影響を与える可能性があります。正式な開腹手術は、手術室での手術時間と専門家による処置が必要であり、通常ベッドサイドでの処置で済む腹膜ドレーンの設置よりも高額になる可能性があります。

開腹手術後に腹膜ドレナージを行うと、それぞれの治療法単独よりもかなり高額になる可能性があります。NECは小児医療と医療に多大な負担をかけているにもかかわらず、最も効果的な解決策は見つかっていません。こうした副作用が市場の成長を抑制する可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 研究者による研究開発の成長
      • 壊死性腸炎の有病率の上昇
    • 抑制要因
      • 壊死性腸炎の手術費用の高さ
    • 機会
      • 企業による投資と資金調達の増加
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析

第6章 COVID-19分析

第7章 タイプ別

  • 古典的壊死性腸炎
  • 輸血関連壊死性腸炎
  • 非定型壊死性腸炎
  • 新生児壊死性腸炎

第8章 薬剤別

  • 抗生物質
    • アンピシリン
    • ゲンタマイシン
    • セフォタキシム
    • バンコマイシン
    • メトロニダゾール
  • 昇圧剤
    • バソプレシン
    • エピネフリン
  • オピオイド鎮痛薬
    • 硫酸モルヒネ
    • フェンタニル
  • 抗真菌薬
    • フルコナゾール

第9章 投与経路別

  • 経口
  • 静脈内投与
  • その他

第10章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第12章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第13章 企業プロファイル

  • Noveome Biotherapeutics, Inc.
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Pfizer Inc.
  • Endo Pharmaceuticals Inc.
  • Par Pharmaceutical
  • AdvaCare Pharma
  • Sanofi
  • Aden Healthcare
  • Mallinckrodt Pharmaceuticals
  • Samex Overseas
  • Anant Pharmaceuticals Pvt. Ltd.

第14章 付録

目次
Product Code: PH6883

Overview

The necrotizing enterocolitis market trends show rising research owing to the rising technological advancements and research studies. Several antibiotics are being launched for the treatment of necrotizing enterocolitis. Antifungals are also utilized for prevention of necrotizing enterocolitis in pediatrics.

Furthermore, rising treatment for necrotizing enterocolitis due to the rising availability of approved antibiotics and increase in the number of necrotizing enterocolitis cases in the market, and an increase in the research and development is driving up the necrotizing enterocolitis market size.

The market is experiencing a growth in demand for drugs from North America areas as a result of the rising advancements in this field. With significant competitors like Noveome Biotherapeutics, Inc., Pfizer Inc., Endo Pharmaceuticals Inc., and Sanofi actively operating in the market, the market will grow in upcoming time.

Dynamics

Growing Research and Development by the Researchers Drive the Growth of the Necrotizing Enterocolitis Market

One of the most common neonatal gastrointestinal illnesses is necrotizing enterocolitis (NEC). The prevalence and death of NEC remain high despite ongoing advances in prevention and treatment. The prevention and treatment of NEC have lately advanced due to new therapeutic approaches such administering breast milk composition, immunotherapy, stem cell therapy, and fecal microbiota transplantation (FMT).

Composition of breast milk, including oligosaccharides, lactoferrin, exosomes generated from breast milk, and other components, has been shown in numerous studies to be one of the most efficient ways to prevent and cure NEC. The most prevalent protein in colostrum (5-6.7 g/L) and the most significant protein in breast milk are both lactoferrin. Intestinal inflammation can be decreased by lactoferrin by preventing the production of pro-inflammatory cytokines including IL-6 and TNF-. In addition to preserving the gut's barrier function, lactoferrin affects the proliferation and death of intestinal epithelial cells.

Numerous preclinical investigations and clinical trials have proven lactoferrin's efficiency in both preventing and treating NEC. By reducing TLR4 expression and boosting crypt cell turnover, oligosaccharides shield intestinal epithelial cells from harm. Exosomes produced from breast milk promote gut growth and have favorable effects on experimental NEC. Intestinal stem cells are vulnerable to oxidative damage, which was controlled via the Wnt/-catenin signaling pathway, but exosomes from breast milk protect them.

Rising Investments and Funding by Companies Creates Opportunities for the Growth of the Market

Noveome Biotherapeutics, Inc., a biopharmaceutical company based in Pittsburgh that is in the clinical stages of developing next-generation biological products for the improvement and reconstruction of cellular structure in inflamed or injured tissues, has closed the first tranche of its $40.2 million Series E financing for a total of $20.7 million. MAK Capital oversaw the funding, and additional funds were contributed by current investors.

Noveome has previously raised $170 million in funding from individual investors along with non-dilutive investment from the Pennsylvania Commonwealth, Allegheny County, and the U.S. Department of Defense. The financing's proceeds will be principally put to use advancing the Company's clinical stage program looking at its patented, ST266, cell-free platform biologic, to treat symptoms of the uncommon pediatric condition necrotizing enterocolitis (NEC).

A unique population composed of human amnion-derived cell cultured into ST266. These cells produce a special collection of cytokines and growth factors termed as the secretome using a patented culture technique, which aids in cellular survival and lowers inflammation.

High Cost of Necrotizing Enterocolitis Surgery will Hamper the Growth of the Market

The management of NEC is very expensive. According to studies, a surgical NEC case in the United States typically costs between $400 000 and $500 000. According to a prospective study that took hospital expenditures into account, the price of surgery NEC ranged from $300,000 to $660,000. The surgical procedure chosen to treat NEC could have a big impact on hospital expenses. A formal laparotomy, which necessitates operating room time and specialist personnel, may be more expensive than the installation of a peritoneal drain, which is normally a quick bedside procedure.

Laparotomy followed by peritoneal drainage may cost considerably more money than each treatment by itself. Despite the fact that NEC places a considerable burden on child health and healthcare spending, the most effective solution has never been found. These side effects may restrain the growth of market.

For more details on this report - Request for Sample

Segment Analysis

The global necrotizing enterocolitis drugs market is segmented based on type, drugs, route of administration and distribution channel.

Owing to High Prevalence, the Classic Necrotizing Enterocolitis from Type Segment Accounted for Approximately 43.4% of the Necrotizing Enterocolitis Market Share

The classic necrotizing enterocolitis category from type held the largest market share in 2022 and is expected to maintain its dominance over the forecast period due to a growth in incidence of necrotizing enterocolitis worldwide. Infants born prior to pregnancy of 28 weeks are typically affected by this most prevalent kind of NEC. Three - six weeks following birth is when classic NEC manifests. The infant is typically stable and performing well. The condition then develops unexpectedly and without prior notice.

A potentially fatal condition known as necrotizing enterocolitis (NEC) nearly exclusively affects newborns. The mortality rate at NEC can reach 50%. The pathophysiology of NEC is intestinal inflammation that results in bacterial invasion, cell death, and colon or intestine necrosis. As NEC worsens, there may be an intestinal perforation, which could result in sepsis, peritonitis, and even death. Bacterial invasion through the intestinal wall is the primary cause of necrotizing enterocolitis.

As a result, the intestine's wall becomes inflamed and loses cells. An intestinal perforation can result in the spilling of intestinal contents in the peritoneum and peritonitis if it is not diagnosed and treated. Low birth weight, prematurity, and formula feeding were identified as the main risk factors among a number of others. Formula feeding with a high osmotic strength has specifically been linked to danger. A function for genetic variables is also possible.

Geographical Penetration

North America Accounted for Approximately 34.2% of the Market Share in 2022, Owing to the Strong Presence of Major Players and Increasing Healthcare Infrastructure Investment

Due to the rising need for necrotizing enterocolitis treatment in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for drugs for necrotizing enterocolitis.

Increasing expenditure on healthcare and rising research studies, advancement of technologies for treatment of infectious disease, and increase in pharmaceutical and biotechnology business establishment across the region are also contributing to the growth of necrotizing enterocolitis market share of this region.

It is also anticipated that the main healthcare organizations' and enterprises' collaborative research projects as well as new product development, which constantly seeks to improve available alternatives, will contribute to the expanding demand. Individuals are becoming more aware of various drugs such as antibiotics for intravenous usage for management purposes, leading to the expansion of the market in this region. The above-mentioned factors further proves the dominance of North America on a global scale.

Competitive Landscape

The major global players in the necrotizing enterocolitis drugs market include Noveome Biotherapeutics, Inc., Pfizer Inc., Endo Pharmaceuticals Inc., Par Pharmaceutical, AdvaCare Pharma, Sanofi, Aden Healthcare, Mallinckrodt Pharmaceuticals, Samex Overseas and Anant Pharmaceuticals Pvt. Ltd. Among others.

COVID-19 Impact Analysis

By Type

  • Classic Necrotizing Enterocolitis
  • Transfusion-associated Necrotizing Enterocolitis
  • Atypical Necrotizing Enterocolitis
  • Term Infant Necrotizing Enterocolitis

By Drugs

  • Antibiotics
    • Ampicillin
    • Gentamycin
    • Cefotaxime
    • Vancomycin
    • Metronidazole
  • Vasopressors
    • Vasopressin
    • Epinephrine
  • Opioid Analgesics
    • Morphine sulfate
    • Fentanyl
  • Antifungal Agents
    • Fluconazole

By Route of Administration

  • Oral
  • Intravenous
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • On May 24, 2022, the U.S. Food and Drug Administration (FDA) has designated rare pediatric diseases (RPDD) and orphan drugs (ODD) for the company's main product ST266 for the management of necrotizing enterocolitis (NEC), according to a press release from Noveome Biotherapeutics, Inc. The company is currently in stages of preparing for clinical trials to look into ST266 treatment for NEC. ST266 is currently being assessed in a number of preclinical animal models.
  • On February 7, 2022, Endo International plc announced the company's Par Sterile Products division has started selling VASOSTRICT, a ready-to-use 100 mL pre-mix bottle of vasopressin injection, USP. The drug's only and first ready-to-use formulation is this one. By removing the requirement to prepare or transport the product prior to patient administration, ready-to-use, or RTU, goods assist in streamlining operations. By lowering the likelihood of a preparation error, this might save waste and expenses, improve convenience and workflow, increase accuracy and compliance, and promote the provision of high-quality patient care.

DMI Opinion:

The global necrotizing enterocolitis market is going to see moderate growth in upcoming years owing to rising usage of antibiotics for necrotizing enterocolitis. Several researches are taking place worldwide for antibiotics development. Numerous advances are taking place leading to the growth of market such as novel antibiotics. According to DMI the necrotizing enterocolitis market will see a decent growth with several novel therapies in the market.

Why Purchase the Report?

  • To visualize the global necrotizing enterocolitis drugs market segmentation based on type, drugs, route of administration, distribution channel and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of necrotizing enterocolitis market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global necrotizing enterocolitis drugs market report would provide approximately 69 tables, 69 figures and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Drugs
  • 3.3. Snippet by Route of Administration
  • 3.4. Snippet by Distribution Channel
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing Research and Development by the Researchers
      • 4.1.1.2. Rising Prevalence of Necrotizing Enterocolitis
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost of Necrotizing Enterocolitis Surgery
    • 4.1.3. Opportunity
      • 4.1.3.1. Rising Investments and Funding by Companies
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Classic Necrotizing Enterocolitis*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Transfusion-associated Necrotizing Enterocolitis
  • 7.4. Atypical Necrotizing Enterocolitis
  • 7.5. Term Infant Necrotizing Enterocolitis

8. By Drugs

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
    • 8.1.2. Market Attractiveness Index, By Drugs
  • 8.2. Antibiotics *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 8.2.3. Ampicillin
    • 8.2.4. Gentamycin
    • 8.2.5. Cefotaxime
    • 8.2.6. Vancomycin
    • 8.2.7. Metronidazole
  • 8.3. Vasopressors
    • 8.3.1. Vasopressin
    • 8.3.2. Epinephrine
  • 8.4. Opioid Analgesics
    • 8.4.1. Morphine sulfate
    • 8.4.2. Fentanyl
  • 8.5. Antifungal Agents
    • 8.5.1. Fluconazole

9. By Route of Administration

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.1.2. Market Attractiveness Index, By Route of Administration
  • 9.2. Oral *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Intravenous
  • 9.4. Other

10. By Distribution Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.1.2. Market Attractiveness Index, By Distribution Channel
  • 10.2. Hospital Pharmacies *
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Retail Pharmacies
  • 10.4. Online Pharmacies

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Spain
      • 11.3.7.5. Italy
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 12.4.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 12.4.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
    • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.4.5.1. Brazil
      • 12.4.5.2. Argentina
      • 12.4.5.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Noveome Biotherapeutics, Inc. *
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Pfizer Inc.
  • 13.3. Endo Pharmaceuticals Inc.
  • 13.4. Par Pharmaceutical
  • 13.5. AdvaCare Pharma
  • 13.6. Sanofi
  • 13.7. Aden Healthcare
  • 13.8. Mallinckrodt Pharmaceuticals
  • 13.9. Samex Overseas
  • 13.10. Anant Pharmaceuticals Pvt. Ltd.

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us